OBI’s Proprietary ADC Platform GlycOBI® Seeks Collaborative Partnerships for Development

On July 26, at the BIO Asia–Taiwan 2024 Company Presentation, OBI Pharma (4174.TWO) showcased its independently developed ADC technology platform, GlycOBI®, to global biotech professionals. OBI aims to collaborate with those interested in ADC development through partnerships or technology licensing.